Trial Profile
Prospective, randomized trial of rapamycin [sirolimus]- and zotarolimus-eluting stents for the reduction of coronary restenosis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Jul 2022
Price :
$35
*
At a glance
- Drugs Probucol (Primary) ; Sirolimus (Primary) ; Zotarolimus
- Indications Coronary artery disease; Coronary artery restenosis; Myocardial infarction; Myocardial ischaemia; Stent thrombosis
- Focus Therapeutic Use
- Acronyms ISAR-TEST-5
- 01 Jul 2022 Results (n=4953) of a post-hoc analysis assessing target and non-target vessel related events at 10 years from two clinical studies: NCT00598676 and NCT00598533 published in the Clinical Research in Cardiology
- 14 Jul 2020 Results published in the Journal of the American College of Cardiology
- 18 Nov 2019 Results assessing very long term outcomes of patients treated with either permanent polymer-based zotarolimus-eluting stent and polymer-free sirolimus- and probucol-eluting stent were presented at the American Heart Association Scientific Sessions 2019